Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc is positioned for significant revenue growth, particularly with its Signatera product, which has shown remarkable performance with a 54% year-over-year volume increase and a quarterly increase of 21,500 patients tested. The company has also reported a strong quarterly revenue beat of approximately $80 million and has raised its revenue guidance for 2025 by $160 million, indicating robust financial expectations. Furthermore, the potential expansion of reimbursement coverage in oncology could enhance average selling prices, improve gross margins, and positively impact operating cash flow.

Bears say

Natera faces a negative outlook primarily due to anticipated erosion of margins stemming from reductions in in-network pricing as the addressable market expands, which may include a higher proportion of average risk patients. Compounding these challenges, any unfavorable developments in regulatory approvals, reimbursement processes, or financial performance could lead to significant stock price declines. Furthermore, uncertainties regarding the adoption of its products in international markets and potential setbacks in securing reimbursement coverage exacerbate the risks associated with Natera's growth and profitability.

Natera (NTRA) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 14 analysts, Natera (NTRA) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $259.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $259.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.